Cristal Therapeutics, PX Biosolutions to Develop Nanotech Vax Platform

Cristal Therapeutics has entered a collaboration with PX Biosolutions to research and develop the application of Cristal’s nanotechnology platform CriVac, for the design of innovative vaccines.
 
The CriVac platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, allowing optimal antigen presentation to dendritic cells.
 
PX Biosolutions, based in Melbourne, Australia, has developed DCtag vaccine formulations against various types of cancer. These vaccine formulations have been tested successfully in animal models.
 
Joost Holthuis, chief executive officer of Cristal Therapeutics said, “We are very excited about this collaboration that fits our strategy to set up product developments with companies active in the vaccine area. We are convinced that we can create additional value for patients and vaccine companies by development of superior vaccine products based on our CriVac technology.”
 
Ann Meulemans, chief executive officer of PX Biosolutions, said, “Our team is very enthusiastic about the possibility to enhance the flexibility of its DCtag platform by using the CriVac technology.”